Scientists Discover Cause Of Leukaemia That Halted Treatment Trial For 'Baby-in-a-Bubble' SyndromeOctober 16, 2003Medical Research Council (MRC) scientists have helped establish the cause of the leukaemia which developed in two young patients taking part in a pioneering gene therapy trial to treat the fatal 'baby-in-a-bubble' syndrome, severe combined immunodeficiency (X-SCID). The trial at the Necker-Enfants Malades clinic in Paris was stopped last year due to the higher than expected number of cases of leukaemia amongst the eight children taking part. After three years of successful gene therapy for X-SCID, leukaemia occurred in the two youngest patients undergoing treatment. Contributing to the international effort to establish quickly why the leukaemia developed, the scientists reveal in the journal Science that in the cases of the two boys, the gene therapy corrected the faulty gene but also activated a cancer-causing gene called LMO2. The scientists suggest that a number of factors might explain why this occurred at a very much higher frequency than expected and that by modifying these factors, scientists will be able to deliver a gene therapy to treat X-SCID which has a much lower risk of causing leukaemia. X-SCID is a genetic disease only found in boys. Those with X-SCID, or 'baby-in-a-bubble' syndrome, are born without an immune system forcing them to live in sterile conditions or risk picking up a life-threatening infection. The disease is caused by a single mutated gene and in the absence of a matched bone marrow donor there is no cure other than gene therapy. Lead MRC researcher, Dr Terry Rabbitts of the MRC Laboratory of Molecular Biology, said: "Cancer is a possible side effect of gene therapy, so any research which will help scientists to modify the treatment to reduce that risk is of great importance. "Although it is anguishing for parents to expose their children to the chance of developing cancer, the benefits of gene therapy for this devastating disease greatly outweigh the risks of the disease itself as X-SCID can only be treated if a matched bone marrow donor is available." Both children who developed leukaemia during the trial underwent treatment for their cancer with chemotherapy and bone marrow transplants. They are alive and well, and in complete clinical remission. Up to one in 50,000 births in the UK are affected by X-SCID. Dr Rabbitts worked on this project in collaboration with scientists from the Babraham Institute and across Europe and the USA. ENDS Medical Research Council |
|||||||||||||||||||||
| Related Gene Therapy Current Events and Gene Therapy News Articles Research reveals lipids' unexpected role in triggering death of brain cells The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators. No-entry zones for AIDS virus The AIDS virus inserts its genetic material into the genome of the infected cell. Scientists of the German Cancer Research Center have now shown for the first time that the virus almost entirely spares particular sites in the human genetic material in this process. This finding may be useful for developing new, specific AIDS drugs. Cornell researchers identify a weak link in cancer cell armor The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Treatment to improve degenerating muscle gains strength A study appearing in Science Translational Medicine puts scientists one step closer to clinical trials to test a gene delivery strategy to improve muscle mass and function in patients with certain degenerative muscle disorders. Iowa State University researcher discovers key to vital DNA, protein interaction A researcher at Iowa State University has discovered how a group of proteins from plant pathogenic bacteria interact with DNA in the plant cell, opening up the possibility for what the scientist calls a "cascade of advances." Scientists successfully reprogram blood cells Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome. Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Caltech researchers show efficacy of gene therapy in mouse models of Huntington's disease Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models. Immunotherapy demonstrates long-term success in treating lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). Toward bold new anti-cancer medicines Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time. More Gene Therapy Current Events and Gene Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||